ProVascTec is a preclinical stage cell treatment firm, to stimulate the development of a novel circulatory system.
ProVascTec has raised $2.9M in total funding. The most recent round was Grant. The last funding was announced in September 2025.
ProVascTec's investors include Eurostars, Disruptive Technologies Innovation Fund.
ProVascTec is headquartered in Cork, Ireland.
ProVascTec is a preclinical stage cell treatment firm, to stimulate the development of a novel circulatory system.
ProVascTec is at the Grant stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"ProVascTec — Funding & Investors." VCBacked, September 25, 2025, https://www.vcbacked.co/company/provasctec. Accessed August 13, 2026.
VCBacked. (2025). ProVascTec — Funding & Investors. Retrieved August 13, 2026, from https://www.vcbacked.co/company/provasctec
{{cite web |title=ProVascTec — Funding & Investors |url=https://www.vcbacked.co/company/provasctec |website=VCBacked |access-date=August 13, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated